vs
Side-by-side financial comparison of STRATA Skin Sciences, Inc. (SSKN) and UNITED SECURITY BANCSHARES (UBFO). Click either name above to swap in a different company.
UNITED SECURITY BANCSHARES is the larger business by last-quarter revenue ($13.5M vs $9.3M, roughly 1.5× STRATA Skin Sciences, Inc.). UNITED SECURITY BANCSHARES runs the higher net margin — 25.2% vs 0.6%, a 24.6% gap on every dollar of revenue. On growth, UNITED SECURITY BANCSHARES posted the faster year-over-year revenue change (13.6% vs -3.0%). UNITED SECURITY BANCSHARES produced more free cash flow last quarter ($19.8M vs $-551.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 3.0%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.
SSKN vs UBFO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.3M | $13.5M |
| Net Profit | $58.0K | $3.4M |
| Gross Margin | 61.8% | — |
| Operating Margin | 5.3% | 31.5% |
| Net Margin | 0.6% | 25.2% |
| Revenue YoY | -3.0% | 13.6% |
| Net Profit YoY | 101.3% | 36.8% |
| EPS (diluted) | $0.14 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.3M | $13.5M | ||
| Q3 25 | $6.9M | $14.0M | ||
| Q2 25 | $7.7M | $12.6M | ||
| Q1 25 | $6.8M | $13.7M | ||
| Q4 24 | $9.6M | $11.9M | ||
| Q3 24 | $8.8M | $13.8M | ||
| Q2 24 | $8.4M | $13.0M | ||
| Q1 24 | $6.8M | $12.8M |
| Q4 25 | $58.0K | $3.4M | ||
| Q3 25 | $-1.6M | $4.0M | ||
| Q2 25 | $-2.6M | $2.2M | ||
| Q1 25 | $-2.1M | $2.7M | ||
| Q4 24 | $-4.6M | $2.5M | ||
| Q3 24 | $-2.1M | $3.8M | ||
| Q2 24 | $-91.0K | $4.3M | ||
| Q1 24 | $-3.4M | $4.2M |
| Q4 25 | 61.8% | — | ||
| Q3 25 | 60.4% | — | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 61.4% | — | ||
| Q3 24 | 60.1% | — | ||
| Q2 24 | 59.0% | — | ||
| Q1 24 | 45.6% | — |
| Q4 25 | 5.3% | 31.5% | ||
| Q3 25 | -16.9% | 40.3% | ||
| Q2 25 | -30.1% | 24.0% | ||
| Q1 25 | -25.0% | 27.5% | ||
| Q4 24 | -44.7% | 27.5% | ||
| Q3 24 | -18.2% | 37.1% | ||
| Q2 24 | -5.7% | 46.4% | ||
| Q1 24 | -42.7% | 45.9% |
| Q4 25 | 0.6% | 25.2% | ||
| Q3 25 | -23.4% | 28.7% | ||
| Q2 25 | -33.6% | 17.2% | ||
| Q1 25 | -31.2% | 19.6% | ||
| Q4 24 | -47.6% | 20.9% | ||
| Q3 24 | -23.6% | 27.7% | ||
| Q2 24 | -1.1% | 33.0% | ||
| Q1 24 | -49.8% | 32.6% |
| Q4 25 | $0.14 | $0.18 | ||
| Q3 25 | $-0.36 | $0.23 | ||
| Q2 25 | $-0.62 | $0.13 | ||
| Q1 25 | $-0.51 | $0.16 | ||
| Q4 24 | $-2.01 | $0.14 | ||
| Q3 24 | $-0.51 | $0.22 | ||
| Q2 24 | $-0.03 | $0.25 | ||
| Q1 24 | $-0.10 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $264.2M |
| Total DebtLower is stronger | $15.3M | — |
| Stockholders' EquityBook value | $2.9M | $139.7M |
| Total Assets | $30.5M | $1.2B |
| Debt / EquityLower = less leverage | 5.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | $264.2M | ||
| Q3 25 | $7.1M | $211.1M | ||
| Q2 25 | $6.0M | $199.5M | ||
| Q1 25 | $6.5M | $198.4M | ||
| Q4 24 | $7.3M | $216.9M | ||
| Q3 24 | $7.1M | $216.8M | ||
| Q2 24 | $5.5M | $166.3M | ||
| Q1 24 | $5.2M | $168.6M |
| Q4 25 | $15.3M | — | ||
| Q3 25 | $15.3M | — | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $15.0M | — | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $15.0M | — | ||
| Q1 24 | $15.0M | — |
| Q4 25 | $2.9M | $139.7M | ||
| Q3 25 | $1.3M | $137.4M | ||
| Q2 25 | $532.0K | $134.3M | ||
| Q1 25 | $3.0M | $132.9M | ||
| Q4 24 | $5.0M | $130.4M | ||
| Q3 24 | $9.4M | $132.9M | ||
| Q2 24 | $9.5M | $127.3M | ||
| Q1 24 | $9.4M | $124.2M |
| Q4 25 | $30.5M | $1.2B | ||
| Q3 25 | $30.7M | $1.2B | ||
| Q2 25 | $29.5M | $1.2B | ||
| Q1 25 | $33.0M | $1.2B | ||
| Q4 24 | $34.9M | $1.2B | ||
| Q3 24 | $39.4M | $1.3B | ||
| Q2 24 | $38.8M | $1.2B | ||
| Q1 24 | $39.2M | $1.2B |
| Q4 25 | 5.28× | — | ||
| Q3 25 | 11.65× | — | ||
| Q2 25 | 28.20× | — | ||
| Q1 25 | 5.04× | — | ||
| Q4 24 | 3.02× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.58× | — | ||
| Q1 24 | 1.59× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-239.0K | $22.1M |
| Free Cash FlowOCF − Capex | $-551.0K | $19.8M |
| FCF MarginFCF / Revenue | -5.9% | 146.0% |
| Capex IntensityCapex / Revenue | 3.4% | 16.8% |
| Cash ConversionOCF / Net Profit | -4.12× | 6.46× |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | $36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-239.0K | $22.1M | ||
| Q3 25 | $-64.0K | $7.0M | ||
| Q2 25 | $-1.9M | $8.7M | ||
| Q1 25 | $-550.0K | $3.0M | ||
| Q4 24 | $703.0K | $19.6M | ||
| Q3 24 | $-302.0K | $5.4M | ||
| Q2 24 | $591.0K | $2.3M | ||
| Q1 24 | $-804.0K | $7.4M |
| Q4 25 | $-551.0K | $19.8M | ||
| Q3 25 | $-1.1M | $6.1M | ||
| Q2 25 | $-2.0M | $8.1M | ||
| Q1 25 | $-749.0K | $2.9M | ||
| Q4 24 | $199.0K | $18.6M | ||
| Q3 24 | $-364.0K | $5.3M | ||
| Q2 24 | $246.0K | $2.0M | ||
| Q1 24 | $-1.5M | $7.0M |
| Q4 25 | -5.9% | 146.0% | ||
| Q3 25 | -15.6% | 43.7% | ||
| Q2 25 | -26.1% | 64.3% | ||
| Q1 25 | -11.0% | 21.2% | ||
| Q4 24 | 2.1% | 156.0% | ||
| Q3 24 | -4.1% | 38.1% | ||
| Q2 24 | 2.9% | 15.5% | ||
| Q1 24 | -22.6% | 54.8% |
| Q4 25 | 3.4% | 16.8% | ||
| Q3 25 | 14.7% | 6.0% | ||
| Q2 25 | 0.8% | 4.6% | ||
| Q1 25 | 2.9% | 0.9% | ||
| Q4 24 | 5.3% | 8.7% | ||
| Q3 24 | 0.7% | 0.7% | ||
| Q2 24 | 4.1% | 2.2% | ||
| Q1 24 | 10.7% | 3.6% |
| Q4 25 | -4.12× | 6.46× | ||
| Q3 25 | — | 1.73× | ||
| Q2 25 | — | 4.01× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 7.87× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 1.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
UBFO
Segment breakdown not available.
